Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer

[1]  Jia-qing Li,et al.  CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. , 2002, International journal of oncology.

[2]  C. Rodríguez,et al.  Serum CYFRA 21‐1 is one of the most reliable tumor markers for breast carcinoma , 2002, Cancer.

[3]  M. Zoli,et al.  Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience) , 2002, American Journal of Gastroenterology.

[4]  H. Kinoshita,et al.  Clinicopathological factors predicting outcome after resection of mass‐forming intrahepatic cholangiocarcinoma , 2001, The British journal of surgery.

[5]  Yasufumi Yamaji,et al.  The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21‐1) in human lung cancer cell lines , 2001, International journal of cancer.

[6]  I. Doweck,et al.  The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease , 2000, British Journal of Cancer.

[7]  A. Heinecke,et al.  CYFRA 21-1 serum analysis in patients with esophageal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  K. Chayama,et al.  Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus–related cirrhosis , 2000, Cancer.

[9]  T. Uenishi,et al.  Surgery for mixed hepatocellular and cholangiocellular carcinoma. , 2000, Hepato-gastroenterology.

[10]  S. Kawasaki,et al.  Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. , 2000, Surgery.

[11]  N. Chalasani,et al.  Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case‐control study , 2000, Hepatology.

[12]  J. Ferlay,et al.  Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18–29 (1999). , 1999, International journal of cancer.

[13]  A. Espasa,et al.  New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. , 1999, Clinical chemistry.

[14]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.

[15]  W. Kwun,et al.  Intrahepatic cholangiocarcinoma in Korea. , 1999, Journal of hepato-biliary-pancreatic surgery.

[16]  J. Olsen,et al.  Risk of liver and other types of cancer in patients with cirrhosis: A nationwide cohort study in Denmark , 1998, Hepatology.

[17]  D. Klimstra,et al.  Surgical treatment of 32 patients with peripheral intrahepatic cholangiocarcinoma , 1998, The British journal of surgery.

[18]  Tomomi Sato,et al.  Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level , 1998, Journal of Gastroenterology.

[19]  K. Takasaki,et al.  Minute nodular intrahepatic cholangiocarcinoma , 1998, Cancer.

[20]  T. Peretz,et al.  Evaluation of tissue polypeptide specific antigen, CYFRA 21‐1, and carcinoembryonic antigen in nonsmall cell lung carcinoma , 1998, Cancer.

[21]  C. Metz,et al.  Maximum likelihood estimation of receiver operating characteristic (ROC) curves from continuously-distributed data. , 1998, Statistics in medicine.

[22]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[23]  A. Bergquist,et al.  Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case‐control study , 1998, Hepatology.

[24]  C A Roe,et al.  Statistical Comparison of Two ROC-curve Estimates Obtained from Partially-paired Datasets , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  S. Chevret,et al.  Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. , 1997, European journal of cancer.

[26]  M. Tsuneyoshi,et al.  Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma , 1996, Cancer.

[27]  Hai-rim Shin,et al.  Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. , 1996, International journal of epidemiology.

[28]  M. Kojiro,et al.  A Clinicopathological study on combined hepatocellular and cholangiocarcinoma , 1996, Journal of gastroenterology and hepatology.

[29]  Y. Chung,et al.  Clinical significance of serum CYFRA 21-1 in gastric cancer. , 1996, British Journal of Cancer.

[30]  N. Lai,et al.  CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. , 1996, Chest.

[31]  J. Fujimoto,et al.  Clinicopathologic spectrum of resected extraductal mass‐forming intrahepatic cholangiocarcinoma , 1995, Cancer.

[32]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[33]  G. Kenter,et al.  Clinical value of pretreatment serum Cyfra 21–1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer , 1995, Cancer.

[34]  F. Izzo,et al.  Identification and Screening of 416 Patients with Chronic Hepatitis at High Risk to Develop Hepatocellular Cancer , 1995, Annals of surgery.

[35]  M. Tsuneyoshi,et al.  Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. , 1995, Human pathology.

[36]  H. Kinoshita,et al.  Hepatolithiasis associated with cholangiocarcinoma , 1995, World Journal of Surgery.

[37]  Roger Williams,et al.  Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. , 1995, Gastroenterology.

[38]  O. Yokosuka,et al.  Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients , 1995, Hepatology.

[39]  M. Fukuoka,et al.  Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. , 1994, British Journal of Cancer.

[40]  H. Kato,et al.  Clinical Usefulness of CYFRA Assay in Diagnosing Lung Cancer: Measurement of Serum Cytokeratin Fragment , 1994, Japanese journal of cancer research : Gann.

[41]  Yuan‐Jen Wang,et al.  Clinical experience in 126 patients with tissue‐proved proximal cholangiocarcinoma , 1994, Journal of gastroenterology and hepatology.

[42]  B. G. Blijenberg,et al.  Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. , 1994, British Journal of Cancer.

[43]  Kenzo Kobayashi,et al.  Prospective study of α‐fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma , 1994 .

[44]  G. Gores,et al.  Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. , 1993, Mayo Clinic proceedings.

[45]  H Dienemann,et al.  CYFRA 21‐1: A new marker in lung cancer , 1993, Cancer.

[46]  Masakazu Yamamoto,et al.  Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular‐cholangiocarcinoma) in Japan , 1993, Cancer.

[47]  K. Chayama,et al.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis , 1993, Hepatology.

[48]  Y. Kawarada,et al.  Diagnosis and treatment of cholangiocellular carcinoma of the liver. , 1990, Hepato-gastroenterology.

[49]  P. Callard,et al.  Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections , 1988, The Journal of pathology.

[50]  R. Warnke,et al.  The Diagnostic Utility of the Keratin Profiles of Hepatocellular Carcinoma and Cholangiocarcinoma , 1988, The American journal of surgical pathology.

[51]  K. Weber,et al.  Differential diagnosis of gastrointestinal carcinomas by using monoclonal antibodies specific for individual keratin polypeptides. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[52]  C. Chu,et al.  Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. , 1986, Gastroenterology.

[53]  Y. Kawarada,et al.  Cholangiocellular carcinoma of the liver. , 1984, American journal of surgery.

[54]  Benjamin Geiger,et al.  The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.

[55]  Randall G. Lee,et al.  Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. , 1998, Annals of surgery.

[56]  S. Fan,et al.  Intrahepatic Cholangiocarcinoma , 1997, World Journal of Surgery.

[57]  S. Fan,et al.  Intrahepatic cholangiocarcinoma. Invited commentary , 1997 .

[58]  W. Su,et al.  A clinical study of 130 patients with biliary tract cancers and periampullary tumors. , 1996, Oncology.

[59]  Shohachi Suzuki,et al.  Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma , 1996, Cancer.

[60]  A. Tamori,et al.  Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. , 1994, Hepatology.

[61]  J. Daurès,et al.  Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. , 1993, Cancer research.

[62]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.